ThematicUpdated 2026-04-19

Best Bio & Healthcare ETFs in 2026

Compare XLV, VHT, IBB, XBI, ARKG by fees, dividend yield, portfolio role, and rebalancing use case. Find the best Bio & Healthcare ETFs for your 2026 portfolio.

Quick Verdict

Bio & Healthcare ETFs: top picks at a glance

Open rebalancing calculator

Best overall

XLV

Largest AUM, Ultra-Low Fee

Lowest fee

XLV

0.09%

Highest yield

XLV

1.6%

ETF Comparison Table

Scan the top ETFs by fee, dividend yield, and portfolio role before using the rebalancing calculator.

RankETFBest forExpenseYield
#1XLVHealth Care Select Sector SPDR FundLargest AUM, Ultra-Low Fee0.09%1.6%
#2VHTVanguard Health Care ETF420 Holdings, Broadest Diversification0.10%1.4%
#3IBBiShares Biotechnology ETFLarge-Cap Biotech Leader0.44%0.20%
#4XBISPDR S&P Biotech ETFEqual-Weight, Small-Cap Biotech Edge0.35%0.15%
#5ARKGARK Genomic Revolution ETFGenomics & Precision Medicine Innovation0.75%-

Use These ETF Picks in the Rebalancing Calculator

Add the top ETF candidates to the portfolio calculator, set target weights, and check whether your current allocation needs buy or sell adjustments.

Open rebalancing calculatorView all ETF recommendationsXLV calculatorVHT calculator

Top 5 Bio & Healthcare ETFs Rankings

1
XLVHealth Care Select Sector SPDR FundLargest AUM, Ultra-Low Fee

XLV is the flagship healthcare ETF tracking S&P 500 healthcare stocks including Johnson & Johnson, UnitedHealth, and Eli Lilly. It provides defensive characteristics and stable dividends, with over $40B in AUM ensuring deep liquidity. Its ultra-low 0.09% expense ratio makes it the ideal long-term core healthcare holding.

Expense 0.09%Div 1.6%
2
VHTVanguard Health Care ETF420 Holdings, Broadest Diversification

VHT tracks the MSCI US Investable Market Health Care Index, covering large-, mid-, and small-cap US healthcare companies — approximately 420 holdings. It offers broader diversification than XLV at a similarly low 0.10% expense ratio, naturally including smaller biotech names. Ideal for investors seeking comprehensive US healthcare exposure in a single ETF.

Expense 0.10%Div 1.4%
3
IBBiShares Biotechnology ETFLarge-Cap Biotech Leader

IBB tracks the Nasdaq Biotechnology Index using market-cap weighting, centering on large-cap biotech leaders such as Amgen, Gilead Sciences, and Vertex Pharmaceuticals. With over $7B in AUM, it is the largest dedicated biotech ETF. Its large-cap tilt provides relatively lower volatility compared to XBI, making it suitable for investors seeking stable biotech growth and pipeline value.

Expense 0.44%Div 0.2%
4
XBISPDR S&P Biotech ETFEqual-Weight, Small-Cap Biotech Edge

XBI tracks the S&P Biotechnology Select Industry Index using equal-weighting, giving small- and mid-cap biotech innovators the same influence as large caps. This approach captures greater upside from breakthrough drug approvals but also amplifies downside risk from clinical failures. Best suited for aggressive investors who want maximum exposure to emerging biotech innovation.

Expense 0.35%Div 0.1%
5
ARKGARK Genomic Revolution ETFGenomics & Precision Medicine Innovation

ARKG is an actively managed ETF by ARK Invest focusing on genomic revolution themes — CRISPR gene editing, genomic sequencing, and cell/gene therapy. It holds names like Exact Sciences, Twist Bioscience, and CRISPR Therapeutics, with low overlap to traditional biotech ETFs. Its active management carries a higher 0.75% expense ratio and significant volatility, so a small 3–5% portfolio allocation is recommended.

Expense 0.75%Div -

Table of Contents

  1. 1. Broad Healthcare ETFs vs. Biotech-Focused ETFs
  2. 2. Key Checkpoints for Healthcare ETF Investors
  3. 3. Portfolio Construction — Core + Satellite Approach

The bio and healthcare sector is driven by powerful structural tailwinds — population aging, pharmaceutical innovation, and AI-powered drug discovery. The US market offers a wide spectrum of healthcare ETFs, from stable large-cap pharma funds to concentrated biotech innovation plays. This guide compares five leading US-listed bio and healthcare ETFs, outlining selection criteria based on investment style and portfolio construction strategies for optimal healthcare sector exposure.

1. Broad Healthcare ETFs vs. Biotech-Focused ETFs

US healthcare ETFs fall into two main categories. First, broad healthcare ETFs like XLV and VHT that invest across the entire healthcare sector — including large pharmaceutical companies (Johnson & Johnson, Eli Lilly), health insurers (UnitedHealth), and medical device makers (Abbott, Medtronic). These offer defensive characteristics and stable dividends, making them suitable as long-term core holdings. Second, biotech-focused ETFs like IBB, XBI, and ARKG that concentrate on biotechnology companies developing new drugs and therapies. These carry higher growth potential but also significantly greater volatility driven by clinical trial outcomes and FDA decisions. A balanced approach combining both types — broad healthcare as core and biotech as satellite — creates a well-diversified healthcare allocation.

2. Key Checkpoints for Healthcare ETF Investors

When selecting a healthcare ETF, several critical factors deserve attention. First, index methodology and construction: XBI uses equal-weighting which amplifies small-cap biotech influence, while IBB uses market-cap weighting favoring large-cap biotech leaders. Second, expense ratio differences: VHT (0.10%) and XLV (0.09%) are extremely cost-efficient, while actively managed ARKG charges 0.75%. Third, FDA regulatory environment: the pace of drug approvals and drug pricing policy changes affect the entire sector. Fourth, patent cliff risk: blockbuster drug patent expirations at major pharmaceutical companies can materially impact earnings and stock prices.

3. Portfolio Construction — Core + Satellite Approach

The most effective way to incorporate healthcare ETFs is through a Core + Satellite strategy. Allocate 10–15% of your total portfolio to XLV or VHT as your core healthcare holding for stable, diversified sector exposure. Add 5–10% in IBB or XBI as a satellite position to capture biotech growth potential. ARKG, given its high-risk/high-reward profile, should be kept to 3–5% at most. Dollar-cost averaging helps smooth out the short-term volatility caused by clinical trial announcements and FDA decisions. Pairing healthcare ETFs with broad market funds like VOO (S&P 500) or QQQ (Nasdaq 100) provides additional sector diversification benefits.

Key Investment Tips

  • 1.Use XLV or VHT as a core long-term healthcare holding and add IBB or XBI as a satellite biotech allocation.
  • 2.Limit total biotech ETF exposure (IBB, XBI, ARKG) to 10–15% of your portfolio.
  • 3.Monitor FDA drug approval calendars and major patent expiration dates for timing insights.
  • 4.Use dollar-cost averaging to reduce the impact of clinical trial-driven volatility.

FAQ

Which US healthcare ETF is best for long-term investment?
For long-term core holdings, XLV or VHT are the best choices. XLV focuses on S&P 500 large-cap healthcare stocks with an extremely low 0.09% expense ratio and deep liquidity. VHT diversifies across 420+ holdings spanning large, mid, and small caps. Choose VHT if you want maximum diversification, or XLV if you prefer large-cap focus with the lowest possible cost.
What is the difference between IBB and XBI?
The key difference is index construction methodology. IBB tracks the Nasdaq Biotechnology Index using market-cap weighting, so large-cap names like Amgen and Gilead dominate. XBI tracks the S&P Biotechnology Select Industry Index using equal weighting, giving small caps the same influence as large caps. As a result, XBI benefits more from small-cap biotech rallies but suffers greater losses in downturns. Choose IBB for more stable biotech exposure and XBI for aggressive growth potential.
What is the appropriate portfolio allocation for bio/healthcare ETFs?
The total healthcare sector allocation (including XLV, VHT) should be 10–20% of your portfolio. Since healthcare represents approximately 12–13% of the S&P 500, use this as your baseline when deciding whether to overweight. Biotech ETFs (IBB, XBI) should be limited to 5–10% given their higher volatility, and thematic ETFs like ARKG should stay within 3–5%. Keep your total combined healthcare exposure below 25%.
Is ARKG worth investing in?
ARKG provides exposure to the long-term megatrend of genomics and precision medicine, including CRISPR gene editing and cell therapy. However, its active management comes with a relatively high 0.75% expense ratio, and the fund experienced a significant drawdown from its 2021 highs, demonstrating substantial volatility. If you have long-term conviction in the genomic revolution, a small 3–5% allocation using dollar-cost averaging can be appropriate — but it should not be a core holding.

Related Guides

How to Choose a Good ETF

Investment Guide guide

Core Principles of Asset Allocation

Investment Guide guide

Time calculators after ETF research

Calculate US market time, work hours, presentation timing, sleep plans, and h:m:s arithmetic.

Time Calculator HubChoose by time taskTime CalculatorAdd and subtract h:m:sWork Hours CalculatorClock-in, breaks, totalsSleep Time CalculatorBedtime and wake-up plansPresentation Time CalculatorScript and slide timingWorld Time CalculatorKorea and US time zones

Apply with the Rebalancing Calculator

Automatically calculate exactly how much to buy and sell to rebalance your portfolio.

Start Rebalancing Calculator
US ETF or stockXLVETF

Health Care Select Sector SPDR Fund Calculator

XLV is an ETF profile used to attach reviewed context to calculator entry flows.

What to Check

  • Used to provide reviewed context in portfolio calculator entry flows.
  • Check exposure, costs, and overlap before using it in a portfolio.

Risks Before Rebalancing

  • It can lose value depending on market conditions.
  • Costs, concentration, and tracking behavior should be reviewed before use.

How to Use the Calculator

  1. 1.Add Health Care Select Sector SPDR Fund to the portfolio.
  2. 2.Enter shares, cash, and target allocation.
  3. 3.Review whether the holding is overweight or underweight and check suggested buy or sell quantities.

Weight Calculation Basis

The rebalancing calculator compares Health Care Select Sector SPDR Fund's current market value, portfolio cash, and other holdings against your target allocation. Actual order quantities can vary with price, FX, fees, and minimum order rules, so use the result as a pre-trade check.

When This Page Helps

Use this page before a new purchase, when setting a target weight, or when deciding whether to trim an oversized Health Care Select Sector SPDR Fund position. In a multi-asset portfolio, reviewing total weight and volatility contribution is more useful than looking at the holding in isolation.

Open Rebalancing CalculatorOptimize Stock Weights